Ipsen and Galderma expand neurotoxins partnership

French drugmaker Ipsen (Euronext: IPN) and global dermatology and skin health company Galderma have expanded the scope of their neurotoxin partnership.

The partnership between the two companies on Dysport/Azzalure (botulinum toxin of type A) now covers most key territories and represents three quarters of the world market for neurotoxins in aesthetic and dermatology indications. Through the new agreement, Galderma will be entitled to develop Ipsen’s neurotoxin pipeline in these areas, including the programs Ipsen has acquired from its purchase of drug developer Syntaxin.

Humberto Antunes, chief executive of Galderma International, now 100% owned by Switzerland-based Nestle (NESN: VX), said: “The reinforcement of Galderma’s partnership with Ipsen increases the ability of both companies to succeed and to meet the needs of both physicians and patients worldwide over many indications. With this agreement, Galderma will be able to significantly expand its commercial reach with Dysport/Azzalure and to gain access to Ipsen’s state-of-the-art neurotoxin platform to meet the full range of skin health needs.”